Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX), Sets a $7 PT

Core Insights - CytomX Therapeutics, Inc. (NASDAQ:CTMX) is identified as a promising stock under $5 with significant upside potential, with a Buy rating and a price target of $7 set by Oppenheimer analyst Matthew Biegler [1] - J.P. Morgan analyst Anupam Rama maintains a Hold rating on the stock, citing the need for more clarity on the safety and efficacy of CytomX's CX-2051, particularly in advanced colorectal cancer [2] - Initial data for CX-2051 shows promising efficacy with a higher objective response rate compared to standard treatments, but concerns about adverse events, especially diarrhea, may impact the drug's safety perception [3] Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing conditionally activated biologics that target the tumor microenvironment [3]